PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 427 (118th)

SAVE Moms and Babies Act of 2023

referredUnited States· United States Congress· EN

Introduced

20 January 2023

Last action

27 January 2023 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Robert Latta, Rep. Harshbarger, Diana [R-TN-1], Robert Aderholt, Guy Reschenthaler, Julia Letlow, Rep. Finstad, Brad [R-MN-1], Rep. Grothman, Glenn [R-WI-6], Blaine Luetkemeyer, Neal Dunn, Mike Bost, Brian Babin, Gary Palmer, Brad Wenstrup, Jake Ellzey, Mary Miller, Christopher Smith, Jim Banks, Rep. Feenstra, Randy [R-IA-4], August Pfluger, Andy Biggs, Scott Franklin, Rep. Weber, Randy K. Sr. [R-TX-14], Rep. Walberg, Tim [R-MI-5], Darin LaHood, Ronny Jackson, Tracey Mann, Troy Balderson, John Rose, Michael Guest, Lauren Boebert, Michael Waltz, Scott Perry, Patrick McHenry, Bob Good, Rep. Carter, Earl L. "Buddy" [R-GA-1], Scott Fitzgerald, Doug Lamborn, Debbie Lesko, William Timmons, Jake LaTurner, Chip Roy, Jerry Carl, H. Griffith, Rep. Yakym, Rudy [R-IN-2], Paul Gosar, Andrew Ogles, Lisa McClain, Russ Fulcher

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Summary

Support And Value Expectant Moms and Babies Act of 2023 or the SAVE Moms and Babies Act of 2023 This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved. Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner. The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient. The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 20 January 2023

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 20 January 2023

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 20 January 2023

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 27 January 2023

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

Sponsors

Showing 48 of 113 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.